ACRV
Acrivon Therapeutics·NASDAQ
--
--(--)
--
--(--)
ACRV fundamentals
During Q4 2025, Acrivon Therapeutics (ACRV) reported revenue of --, a YoY change of 0.00%. Net income was -18.98M, a YoY change of 16.85%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 2.67M -- | 4.27M -- | 7.21M -- | 5.92M -- | 9.57M +258.48% | 9.95M +132.90% | 14.39M +99.57% | 15.52M +161.94% | 16.14M +68.53% | 21.05M +111.69% | 17.67M +22.75% | 21.44M +38.13% | 25.14M +55.79% | 24.95M +18.53% | 21.66M +22.61% | 22.65M +5.65% | 19.69M -21.69% | 20.12M -19.39% | 84.11M -- |
Selling, General and Administrative Expenses | 455.00K -- | 1.22M -- | 1.14M -- | 1.85M -- | 1.63M +258.90% | 4.08M +235.50% | 4.63M +305.16% | 5.00M +170.51% | 5.87M +259.46% | 5.58M +36.54% | 6.20M +33.66% | 6.41M +28.27% | 6.28M +6.92% | 6.32M +13.43% | 6.25M +0.86% | 6.47M +0.86% | 6.04M -3.78% | 5.37M -15.09% | 24.12M -- |
General and Administrative Expenses | -- -- | 2.47M -- | -- -- | -- -- | -- -- | 8.71M +253.12% | -- -- | -- -- | 5.87M -- | 5.58M -35.98% | 6.20M -- | 6.41M -- | 6.28M +6.92% | 6.32M +13.43% | 6.25M +0.86% | 6.47M +0.86% | 6.04M -3.78% | 5.37M -15.09% | 24.12M -- |
Research and Development Expenses | 2.22M -- | 3.05M -- | 6.07M -- | 4.08M -- | 7.94M +258.39% | 5.86M +92.01% | 9.76M +60.81% | 10.52M +158.06% | 10.27M +29.27% | 15.48M +164.04% | 11.47M +17.58% | 15.03M +42.81% | 18.86M +83.73% | 18.63M +20.36% | 15.41M +34.35% | 16.18M +7.70% | 13.65M -27.65% | 14.75M -20.85% | 59.99M -- |
Operating Income | -2.67M -- | -4.27M -- | -7.21M -- | -5.92M -- | -9.57M -258.48% | -9.95M -132.90% | -14.39M -99.57% | -15.52M -161.94% | -16.14M -68.53% | -21.05M -111.69% | -17.67M -22.75% | -21.44M -38.13% | -25.14M -55.79% | -24.95M -18.53% | -21.66M -22.61% | -22.65M -5.65% | -19.69M +21.69% | -20.12M +19.39% | -84.11M -- |
Non-Operating Income (Loss) | 231.00K -- | -73.00K -- | -8.00K -- | 105.00K -- | 377.00K +63.20% | 1.02M +1491.78% | 1.64M +20562.50% | 1.61M +1429.52% | 1.67M +343.24% | 1.80M +77.26% | 1.18M -27.79% | 2.64M +64.32% | 2.70M +61.52% | 2.12M +17.88% | 1.98M +67.68% | 1.64M -37.74% | 1.45M -46.17% | 1.13M -46.73% | 6.21M -- |
Gain (Loss) on Change in Fair Value | -- -- | -80.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | 231.00K -- | 7.00K -- | -8.00K -- | 105.00K -- | 377.00K +63.20% | 1.02M +14414.29% | -170.00K -2025.00% | -164.00K -256.19% | -97.00K -125.73% | 109.00K -89.27% | -264.00K -55.29% | -55.00K +66.46% | 1.00K +101.03% | -240.00K -320.18% | -14.00K +94.70% | -87.00K -58.18% | -53.00K -5400.00% | -116.00K +51.67% | -270.00K -- |
Net Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -1.81M -- | -1.77M -- | -1.77M -- | -1.69M -- | -1.45M +19.98% | -2.69M -52.20% | -2.70M -52.60% | -2.36M -39.66% | -2.00M -38.04% | -1.73M +35.78% | -1.51M +44.18% | -1.25M +47.23% | -6.48M -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 1.81M -- | 1.77M -- | 1.77M -- | 1.69M -- | 1.45M -19.98% | 2.69M +52.20% | 2.70M +52.60% | 2.36M +39.66% | 2.00M +38.04% | 1.73M -35.78% | 1.51M -44.18% | 1.25M -47.23% | 6.48M -- |
Pretax Income From Continuing Operations | -2.44M -- | -4.34M -- | -7.22M -- | -5.82M -- | -9.20M -276.97% | -8.93M -105.60% | -12.76M -76.68% | -13.91M -139.07% | -14.47M -57.27% | -19.25M -115.61% | -16.49M -29.24% | -18.80M -35.10% | -22.44M -55.13% | -22.83M -18.59% | -19.68M -19.37% | -21.01M -11.75% | -18.23M +18.75% | -18.98M +16.85% | -77.91M -- |
Income Tax Expense | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -2.44M -- | -4.34M -- | -7.22M -- | -5.82M -- | -9.20M -276.97% | -8.93M -105.60% | -12.76M -76.68% | -13.91M -139.07% | -14.47M -57.27% | -19.25M -115.61% | -16.49M -29.24% | -18.80M -35.10% | -22.44M -55.13% | -22.83M -18.59% | -19.68M -19.37% | -21.01M -11.75% | -18.23M +18.75% | -18.98M +16.85% | -77.91M -- |
Net Income Attributable to Owners of the Company | -2.44M -- | -4.34M -- | -7.22M -- | -5.82M -- | -9.20M -276.97% | -8.93M -105.60% | -12.76M -76.68% | -13.91M -139.07% | -14.47M -57.27% | -19.25M -115.61% | -16.49M -29.24% | -18.80M -35.10% | -22.44M -55.13% | -22.83M -18.59% | -19.68M -19.37% | -21.01M -11.75% | -18.23M +18.75% | -18.98M +16.85% | -77.91M -- |
Net Income Attributable to Common Stockholders | -2.44M -- | -4.34M -- | -7.22M -- | -5.82M -- | -9.20M -276.97% | -8.93M -105.60% | -12.76M -76.68% | -13.91M -139.07% | -14.47M -57.27% | -19.25M -115.61% | -16.49M -29.24% | -18.80M -35.10% | -22.44M -55.13% | -22.83M -18.59% | -19.68M -19.37% | -21.01M -11.75% | -18.23M +18.75% | -18.98M +16.85% | -77.91M -- |
Other Comprehensive Income | -- -- | 0 -- | -- -- | -- -- | -133.00K -- | 38.00K -- | 104.00K -- | -436.00K -- | 125.00K +193.98% | 219.00K +476.32% | 13.00K -87.50% | 51.00K +111.70% | 801.00K +540.80% | -335.00K -252.97% | -164.00K -1361.54% | -177.00K -447.06% | 6.00K -99.25% | -1.00K +99.70% | -336.00K -- |
Total Comprehensive Income | -2.44M -- | -4.34M -- | -7.22M -- | -5.82M -- | -9.33M -282.42% | -8.89M -104.72% | -12.65M -75.24% | -14.35M -146.56% | -14.34M -53.69% | -19.03M -114.07% | -16.47M -30.20% | -18.75M -30.64% | -21.64M -50.90% | -23.17M -21.71% | -19.84M -20.46% | -21.18M -12.99% | -18.23M +15.77% | -18.99M +18.04% | -78.24M -- |
Total Comprehensive Income Attributable to Owners of the Company | -2.44M -- | -4.34M -- | -7.22M -- | -5.82M -- | -9.33M -282.42% | -8.89M -104.72% | -12.65M -75.24% | -14.35M -146.56% | -14.34M -53.69% | -19.03M -114.07% | -16.47M -30.20% | -18.75M -30.64% | -21.64M -50.90% | -23.17M -21.71% | -19.84M -20.46% | -21.18M -12.99% | -18.23M +15.77% | -18.99M +18.04% | -78.24M -- |
Basic EPS | -1.38 -- | -- -- | -4.08 -- | -3.29 -- | -5.17 -274.64% | -0.41 -- | -0.58 +85.78% | -0.63 +80.85% | -0.66 +87.23% | -0.85 -107.32% | -0.73 -25.86% | -0.52 +17.46% | -0.59 +10.61% | -0.73 +14.12% | -0.51 +30.14% | -0.55 -5.77% | -0.47 +20.34% | -0.6 +17.81% | -2.13 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.66 -- | -- -- | -0.73 -- | -0.52 -- | -0.59 +10.61% | -- -- | -0.51 +30.14% | -0.55 -5.77% | -0.47 +20.34% | -- -- | -- -- |
Diluted EPS | -1.38 -- | -- -- | -4.08 -- | -3.29 -- | -5.17 -274.64% | -- -- | -0.58 +85.78% | -0.63 +80.85% | -0.66 +87.23% | -- -- | -0.73 -25.86% | -0.52 +17.46% | -0.59 +10.61% | -- -- | -0.51 +30.14% | -0.55 -5.77% | -0.47 +20.34% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.66 -- | -- -- | -0.73 -- | -0.52 -- | -0.59 +10.61% | -- -- | -0.51 +30.14% | -0.55 -5.77% | -0.47 +20.34% | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for Acrivon Therapeutics next quarter?What does Acrivon Therapeutics do and what are its main business segments?What guidance did Acrivon Therapeutics's management provide for the next earnings period?What factors drove the changes in Acrivon Therapeutics's revenue and profit?What were the key takeaways from Acrivon Therapeutics’s earnings call?Did Acrivon Therapeutics beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Acrivon Therapeutics year over year?What is Acrivon Therapeutics's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
